Sagimet BiosciencesSTU:0O2 +1.66%10 3-Year EBITDA Growth Rate is -7.90% as of Mar. 2026. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,141 Biotechnology companies, Sagimet Biosciences ranks worse than 77.65% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was -7.90% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was -27.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sagimet Biosciences was -7.90% per year. The lowest was -78.90% per year. And the median was -23.65% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Sagimet Biosciences 3-Year EBITDA Growth Rate Related Terms
STU:0O2 vs NGNE, UPB, STTK: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Sagimet Biosciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of -7.90% mean?
Sagimet Biosciences (STU:0O2) has a 3-Year EBITDA Growth Rate of -7.90% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sagimet Biosciences and its competitors. According to the industry distribution chart, Sagimet Biosciences ranks #886 out of 1141 companies in the Biotechnology industry, placing it in the top 77.7%.
Is Sagimet Biosciences' 3-Year EBITDA Growth Rate too high?
Sagimet Biosciences' current 3-Year EBITDA Growth Rate is -7.90%. Based on the distribution chart, Sagimet Biosciences ranks #886 out of 1141 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' 3-Year EBITDA Growth Rate compare to NGNE and UPB?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #886 out of 1141 companies for 3-Year EBITDA Growth Rate. This places Sagimet Biosciences in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 14.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.90, based on 1,141 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Sagimet Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current 3-Year EBITDA Growth Rate is -7.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current 3-Year EBITDA Growth Rate of -7.90%. The current 3-Year EBITDA Growth Rate is -7.90%. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current 3-Year EBITDA Growth Rate is -7.90% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 